Last updated: 2026-10-12 22:41:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Align Technology Inc. (ALGN) operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector and is listed on NASDAQ. The stock is currently priced at $140,52, with a market capitalisation of $10,14B and a P/E ratio of 24,51. Over the past 52 weeks, its price has ranged from $126,26 to $200,44. This page covers its latest market performance, valuation, price trends and company information.
$10,14B | |
$143,23 | |
$737,45 | |
$4,88 | |
$142,71 | |
665,51K | |
914,18K | |
24,51 | |
$200,44 | |
$126,26 | |
-- | |
-- |
Align Technology Inc. (ALGN) is trading at $140,64 in after-hours trading as of 2026-10-12 22:32:00, down 1,45% ($2,07) from the regular-session close of $142,71.
After-hours trading shows how investors are pricing ALGN after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Align Technology Inc. (ALGN) moved from $145,35 to $140,52, representing a decline of 3,32% ($4,83).
The stock traded between $138,05 and $147,09 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 996,31 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19,2%
ALGN is currently trading at $140,52, placing it 19,2% of the way from its 52-week low of $126,26 to its 52-week high of $200,44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
| Industry | ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES |
| Employees | 20435 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Align Technology Inc. (ALGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.